Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pharmacokinetic Study of Posaconazole Boosted Fosamprenavir.

Next Previous
Trial Profile

Pharmacokinetic Study of Posaconazole Boosted Fosamprenavir.

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Sep 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fosamprenavir (Primary) ; Posaconazole (Primary) ; Ritonavir (Primary)
  • Indications HIV infections
  • Focus Pharmacokinetics
  • Acronyms EPOS

Most Recent Events

  • 28 Jul 2010 Results have been published in the Journal of Antimicrobial Chemotherapy.
  • 19 Feb 2010 Results presented at the 17th Conference on Retroviruses and Opportunistic Infections (CROI).
  • 09 Dec 2009 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top